NVTR - Nuvectra Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.5700
+0.0400 (+1.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.5300
Open2.5300
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's Range2.4500 - 2.6200
52 Week Range2.4500 - 25.1700
Volume251,492
Avg. Volume389,411
Market Cap46.47M
Beta (3Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-3.2540
Earnings DateJul 31, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • GlobeNewswire17 hours ago

    Nuvectra to Report Second Quarter 2019 Financial Results on July 31, 2019

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2019 on Wednesday, July 31, 2019 after market close. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 3264026.

  • Is Nuvectra Corporation (NVTR) A Good Stock To Buy?
    Insider Monkey22 days ago

    Is Nuvectra Corporation (NVTR) A Good Stock To Buy?

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

  • Should You Be Concerned About Nuvectra Corporation's (NASDAQ:NVTR) Historical Volatility?
    Simply Wall St.24 days ago

    Should You Be Concerned About Nuvectra Corporation's (NASDAQ:NVTR) Historical Volatility?

    If you own shares in Nuvectra Corporation (NASDAQ:NVTR) then it's worth thinking about how it contributes to the...

  • GlobeNewswirelast month

    Nuvectra® to Participate in Two Upcoming Investor Conferences

    PLANO, Texas, June 12, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that members of management are scheduled to.

  • GlobeNewswirelast month

    Nuvectra Files Regulatory Submission with FDA for Algovita® Full-Body MR-Conditional Approval

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration (FDA) for full-body MR-conditional approval for the Company’s Algovita SCS system. Fred Parks, Chief Executive Officer, commented, “We believe full-body MR-conditional approval in the United States, in addition to Algovita’s full-body MR-conditional CE Mark approval, will supplement our existing competitive advantages and expand the number of eligible patients. This submission, pending regulatory approval from the FDA, would position the Company to achieve MR-conditional approval at or around year end 2019 following a 180-day review process.

  • GlobeNewswire2 months ago

    Nuvectra Highlights Positive Preliminary Algovita® Clinical Data at the INS 14th Annual World Congress

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today preliminary Algovita® clinical data from its U.S. and EU multi-center, single-arm study demonstrating lead fracture and migration rates that were below industry average. The study data was presented by Robert Levy, MD, PhD, a board-certified neurological surgeon and member of Nuvectra’s Medical Advisory Board, at the International Neuromodulation Society (INS) 14th Annual World Congress in Sydney, Australia. The preliminary results are based on clinical outcomes for 75 patients up to approximately 7 months following permanent implantation at 18 clinical sites.

  • Have Insiders Been Buying Nuvectra Corporation (NASDAQ:NVTR) Shares?
    Simply Wall St.2 months ago

    Have Insiders Been Buying Nuvectra Corporation (NASDAQ:NVTR) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • GlobeNewswire2 months ago

    Nuvectra® Announces Departure of COO & CFO Walter Z. Berger

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced that Walter Z. Berger has resigned as Nuvectra’s Chief Operating Officer and Chief Financial Officer to pursue another business opportunity, effective May 24, 2019. The Board of Directors accepted Mr. Berger’s resignation and has appointed Ms. Jennifer Kosharek, the Company’s current Vice President, Controller and Principal Accounting Officer, as interim Chief Financial Officer as it initiates a search for a successor.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NVTR earnings conference call or presentation 1-May-19 8:30pm GMT

    Q1 2019 Nuvectra Corp Earnings Call

  • Nuvectra Corporation Common Stock (NVTR) Q1 2019 Earnings Call Transcript
    Motley Fool3 months ago

    Nuvectra Corporation Common Stock (NVTR) Q1 2019 Earnings Call Transcript

    NVTR earnings call for the period ending March 31, 2019.

  • Nuvectra (NVTR) Reports Q1 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Nuvectra (NVTR) Reports Q1 Loss, Misses Revenue Estimates

    Nuvectra (NVTR) delivered earnings and revenue surprises of -27.69% and -12.79%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Nuvectra: 1Q Earnings Snapshot

    The Plano, Texas-based company said it had a loss of 83 cents per share. The medical device company posted revenue of $11.1 million in the period, which did not meet Street forecasts. Three analysts surveyed ...

  • GlobeNewswire3 months ago

    Nuvectra® Reports First Quarter 2019 Financial Results

    PLANO, Texas, May 01, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended.

  • ACCESSWIRE3 months ago

    Nuvectra Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Nuvectra Corp. (NASDAQ: NVTR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 1, 2019 at 4:30 PM Eastern Time. ...

  • Nuvectra (NVTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks3 months ago

    Nuvectra (NVTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    Nuvectra to Report First Quarter 2019 Financial Results on May 1, 2019

    PLANO, Texas, April 22, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for.

  • Are Nuvectra Corporation (NASDAQ:NVTR) Shareholders Getting A Good Deal?
    Simply Wall St.3 months ago

    Are Nuvectra Corporation (NASDAQ:NVTR) Shareholders Getting A Good Deal?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Nuvectra Corporation (NASDAQ:NVTR) shareholders, and potential investors, need to understand how much cash the business makes...

  • ACCESSWIRE4 months ago

    FDA Events Can Send Stocks Soaring: Here's One That No One Is Talking About

    Biogen's (BIIG) latest clinical trial failure is a testament to the difficulty in developing drugs for Alzheimer's, which is littered with failures in the last ten years. But other neurology fields have ...

  • GlobeNewswire4 months ago

    Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl, III as Chairman of the Board of Directors, following Dr. Joseph A. Miller’s retirement from the Board, effective immediately. Concurrently, Jane J. Song was appointed as an independent member of the Company’s Board of Directors and as a member of the Board’s Governance and Nomination Committee. Mr. Bihl stated, “I am honored to enter my new role as Chairman of the Board and welcome Jane, an industry leader, to Nuvectra.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of NVTR earnings conference call or presentation 28-Feb-19 9:30pm GMT

    Q4 2018 Nuvectra Corp Earnings Call

  • GuruFocus.com4 months ago

    Nuvectra Corp (NVTR) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Nuvectra Corp (NASDAQ:NVTR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • GlobeNewswire5 months ago

    Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results

    PLANO, Texas, Feb. 28, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full.

  • How Financially Strong Is Nuvectra Corporation (NASDAQ:NVTR)?
    Simply Wall St.5 months ago

    How Financially Strong Is Nuvectra Corporation (NASDAQ:NVTR)?

    While small-cap stocks, such as Nuvectra Corporation (NASDAQ:NVTR) with its market cap of US$246m, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • GlobeNewswire5 months ago

    Nuvectra® to Present at 39th Annual Cowen Healthcare Conference

    PLANO, Texas, Feb. 26, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks, PhD, Chief Executive Officer,.